Dual drug-loaded topical delivery of photodynamically active lipid-based formulation for combination therapy of cutaneous melanoma

Rupesh Jain ^a, Milan Paul ^b, Sri Ganga Padaga ^b, Sunil Kumar Dubey ^{a,c}[†], Swati Biswas ^{b*}, Gautam Singhvi ^{a*}.

^a Department of Pharmacy, Birla Institute of Technology and Science, Pilani (BITS-PILANI), Pilani Campus, Rajasthan, India

^b Department of Pharmacy, Birla Institute of Technology and Science, Pilani (BITS-PILANI), Hyderabad Campus, Telangana, India.

^c R&D Healthcare Division, Emami Ltd., 13, BT Road, Belgharia, Kolkata 700056, India († Present Affiliation)

SUPPLEMENTARY MATERIAL

	In	dependent vari	Response variables		
Batch No.	Lipid (mg)	Surfactant (%)	Sonication (min)	Size (nm)	Entrapment Efficiency (%)
1	100	1.50	5	65.33 ± 1.53	45.41 ± 1.52
2	200	1.50	1	214.67 ± 5.03	65.97 ± 1.97
3	100	2.50	3	57.83 ± 1.61	67.47 ± 0.64
4	150	0.50	5	174.33 ± 4.51	45.43 ± 1.19
5	150	1.50	3	84.17 ± 2.02	75.63 ± 2.16
6	150	1.50	3	80.87 ± 2.01	75.60 ± 0.88
7	150	1.50	3	92.90 ± 2.89	71.00 ± 1.74
8	150	2.50	1	193.90 ± 4.55	59.53 ± 0.60
9	150	1.50	3	88.67 ± 3.51	72.78 ± 0.66
10	150	0.50	1	220.00 ± 5.57	43.83 ± 0.35
11	200	2.50	3	89.23 ± 3.61	80.20 ± 2.30
12	150	1.50	3	94.10 ± 4.48	73.80 ± 0.61
13	100	1.50	1	158.67 ± 6.51	45.77 ± 0.67
14	150	2.50	5	54.07 ± 3.66	62.07 ± 0.75
15	100	0.50	3	102.13 ± 3.07	43.73 ± 0.40
16	200	0.50	3	198.23 ± 3.25	67.83 ± 0.58
17	200	1.50	5	90.27 ± 1.59	80.73 ± 3.19

Table T1. Design and characterizations of Dual drug loaded lipidic nanocarriers (DDLN)

Table T2. ANOVA for regression coefficients for Box Behnken designed effects (linear, quadratic, and interaction) against the CQAs i.e., dependent variables (particle size and entrapment efficiency) to establish the best fitted quadratic equation.

Effect	Variable	Particle size		Entrapment efficiency	
		F- value	P- value	F- value	P- value
	Α	58.37	< 0.0001	118.86	< 0.0001
Linear effect	В	142.77	< 0.0001	65.71	< 0.0001
	С	236.42	< 0.0001	5.54	< 0.0001
	AB	11.64	0.0077	5.21	0.0484
Interaction effect	BC	20.70	0.0014	-	-
	AC	-	-	6.29	0.0334
	A2	-	-	-	-
Quadratic term	B2	33.81	0.0003	28.10	0.0005
	C2	97.00	< 0.0001	81.11	< 0.0001

 Table T3. Validation batch by numerical method

Responses	Predicted results	Actual results	% Relative
Particle size (nm)	92.12 ± 4.25	94.50 ± 4.58	-0.761
Entrapment efficiency (%)	77.66 ± 1.57	78.73 ± 1.31	-1.382

Kinetic model	DDLN curcumin				Free drug curcumin			
	R ²	k	AIC	MSC	R ²	k	AIC	MSC
Zero order	0.6480	4.962	65.0120	0.7940	0.8167	9.599	53.3398	1.0529
First order	0.9937	0.122	32.7659	4.8248	0.9790	0.213	38.1573	3.2219
Higuchi	0.9333	19.934	51.6998	2.4580	0.9269	27.710	46.9003	1.9729
Koresmeyer peppas	0.9386 n = 0.548	17.727	53.0350	2.2911	0.9408 n= 0.608	22.443	47.4264	1.8977
	DDLN chlorin e6				Free drug chlorin e6			
Kinetic model		DDLN ch	llorin e6	<u> </u>	F	ree drug	chlorin e6	
Kinetic model	R ²	DDLN ch	llorin e6 AIC	MSC	R ²	ree drug k	chlorin e6 AIC	MSC
Kinetic model Zero order	R² 0.8448	DDLN ch k 4.914	AIC 58.7186	MSC 1.6129	R ² 0.9740	ree drug k 13.781	chlorin e6 AIC 33.8377	MSC 2.9149
Kinetic model Zero order First order	R² 0.8448 0.9885	DDLN ch k 4.914 0.103	AIC 58.7186 37.9272	MSC 1.6129 4.2118	R ² 0.9740 0.9545	ree drug k 13.781 0.272	chlorin e6 AIC 33.8377 37.2053	MSC 2.9149 2.3536
Kinetic model Zero order First order Higuchi	R² 0.8448 0.9885 0.9434	DDLN ch k 4.914 0.103 19.144	AIC 58.7186 37.9272 50.6484	MSC 1.6129 4.2118 2.6217	R ² 0.9740 0.9545 0.9416	ree drug k 13.781 0.272 32.899	chlorin e6 AIC 33.8377 37.2053 38.6994	MSC 2.9149 2.3536 2.1046

Table T4. Release mechanism of DDLN formulation and free drugs by curve fitting method.



Figure F1. Stability data of DDLN Gel at different storage conditions. Assay of DDLN gel at 25 °C for 90 days A); Assay of DDLN gel at 2-8 °C for 90 days B); Entrapment efficiency of DDLN formulation containing CUR and Chl e6 at 25 °C for 90 days C); Entrapment efficiency of DDLN formulation containing CUR and Chl e6 at 2-8 °C for 90 days D); DDLN particle size data for 90 days at 2-8 °C and 25 °C represents in graph E).